EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of rosuvastatin as add-on to standard treatment on disease severity, inflammatory, and angiogenic biomarkers in chronic plaque psoriasis patients having cardiovascular risk: A nonrandomized, assessor blind, controlled clinical trial (RoSInA-P3 trial)

Shaveta Siwach, Niti Mittal, Surabhi Dayal, Nidhi Goel, Mohini Asija, Anshita Mishra

Perspectives in Clinical Research · 2026-10 · 17 (4) · 224-229

DOI: 10.4103/picr.picr_146_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Perspectives in Clinical Research, online erschienen am 17.01.2026. Verfasst von Shaveta Siwach und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Pt. B. D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to explore the effect of rosuvastatin on disease severity, inflammatory, and angiogenic markers in plaque psoriasis patients having cardiovascular (CV) risk. Methodology: In this nonrandomized, assessor blind clinical trial, plaque psoriasis patients were allocated to rosuvastatin add-on ( n = 24) or standard therapy group ( n = 24) depending upon baseline CV risk. The primary outcome was the mean change in psoriasis area and severity index (PASI) score at 12 weeks from baseline. Other outcomes were PASI 50 and PASI 75, change in dermatology life quality index (DLQI) scores, lipid profile, serum high-sensitivity C-reactive protein, vascular endothelial growth factor, and interleukin-17 levels.

Results

At 12 weeks, the mean (standard deviation) change from baseline PASI was −2.34 (2.81) in the rosuvastatin and −1.93 (3.33) standard therapy groups ( P = 0.38). The rosuvastatin group exhibited an earlier and consistent improvement in disease severity; 3 (17.64%) patients receiving rosuvastatin achieved PASI 50 at 4 weeks compared to none in the standard. The difference in mean change in DLQI and biochemical parameters between the two groups was not statistically significant. Both the groups had comparable safety profile.

Conclusion

Rosuvastatin may be considered a potential add-on treatment in plaque psoriasis patients having intermediate or high CV risk.

Schlagwörter

Stichwörter der Autor:innen

Antiangiogenicanti-inflammatorydermatology life quality indexplaque psoriasisrosuvastatin

Autor:innen und Institutionen

  • Department of Pharmacology, Pt. B. D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Dermatology, Pt. B. D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Microbiology, Pt. B. D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Internal Medicine, Pt. B. D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
  • Department of Community Medicine, Maulana Azad Medical College, New Delhi, India.

Zitieren

APA

Siwach, S., Mittal, N., Dayal, S., Goel, N., Asija, M., & Mishra, A. (2026). Effect of rosuvastatin as add-on to standard treatment on disease severity, inflammatory, and angiogenic biomarkers in chronic plaque psoriasis patients having cardiovascular risk: A nonrandomized, assessor blind, controlled clinical trial (RoSInA-P3 trial). Perspectives in Clinical Research, 17(4), 224-229. https://doi.org/10.4103/picr.picr_146_25

Vancouver

Siwach S, Mittal N, Dayal S, Goel N, Asija M, Mishra A. Effect of rosuvastatin as add-on to standard treatment on disease severity, inflammatory, and angiogenic biomarkers in chronic plaque psoriasis patients having cardiovascular risk: A nonrandomized, assessor blind, controlled clinical trial (RoSInA-P3 trial). Perspectives in Clinical Research. 2026;17(4):224-229. doi:10.4103/picr.picr_146_25

BibTeX
@article{Siwach2026,
  author = {Siwach, Shaveta and Mittal, Niti and Dayal, Surabhi and Goel, Nidhi and Asija, Mohini and Mishra, Anshita},
  title = {Effect of rosuvastatin as add-on to standard treatment on disease severity, inflammatory, and angiogenic biomarkers in chronic plaque psoriasis patients having cardiovascular risk: A nonrandomized, assessor blind, controlled clinical trial (RoSInA-P3 trial)},
  journal = {Perspectives in Clinical Research},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {224--229},
  doi = {10.4103/picr.picr_146_25}
}
Kostenlos starten →